Lee S Rosen

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
    Lee S Rosen
    UCLA Department of Medicine, Los Angeles, CA90404, USA
    Clin Cancer Res 18:4820-9. 2012
  2. doi request reprint A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors
    Lee S Rosen
    UCLA Division of Hematology Oncology, Los Angeles, CA 90404, USA
    Clin Cancer Res 17:7754-64. 2011
  3. doi request reprint Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors
    Lee S Rosen
    Premiere Oncology, Santa Monica, California, USA
    Clin Cancer Res 18:3414-27. 2012
  4. pmc The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
    Lee S Rosen
    Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA
    BMC Cancer 13:242. 2013
  5. ncbi request reprint Inhibitors of the vascular endothelial growth factor receptor
    Lee S Rosen
    Cancer Institute Medical Group, St John s Health Center, 2001 Santa Monica Boulevard, Suite 560W, Santa Monica, CA 90404, USA
    Hematol Oncol Clin North Am 16:1173-87. 2002
  6. ncbi request reprint Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Los Angeles, California 90025, USA
    Cancer 100:2613-21. 2004
  7. ncbi request reprint Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies
    Lee S Rosen
    Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA
    Clin Cancer Res 10:3689-98. 2004
  8. ncbi request reprint Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
    Lee S Rosen
    Cancer Institute Medical Group, Santa Monica, California, USA
    Cancer 100:36-43. 2004
  9. doi request reprint Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
    Roy S Herbst
    Premiere Oncology, California, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404, USA
    J Clin Oncol 27:3557-65. 2009
  10. doi request reprint Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
    Jonathan W Goldman
    David Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA
    Cancer 118:5903-11. 2012

Detail Information

Publications28

  1. pmc A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
    Lee S Rosen
    UCLA Department of Medicine, Los Angeles, CA90404, USA
    Clin Cancer Res 18:4820-9. 2012
    ..Patients and Methods: Patients received escalating doses of intravenous TRC105 until disease progression or unacceptable toxicity using a standard 3 + 3 phase I design...
  2. doi request reprint A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors
    Lee S Rosen
    UCLA Division of Hematology Oncology, Los Angeles, CA 90404, USA
    Clin Cancer Res 17:7754-64. 2011
    ..This open-label, phase I, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of tivantinib in patients with advanced or metastatic solid tumors refractory to standard therapy...
  3. doi request reprint Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors
    Lee S Rosen
    Premiere Oncology, Santa Monica, California, USA
    Clin Cancer Res 18:3414-27. 2012
    ....
  4. pmc The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
    Lee S Rosen
    Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA
    BMC Cancer 13:242. 2013
    ..Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder size and function...
  5. ncbi request reprint Inhibitors of the vascular endothelial growth factor receptor
    Lee S Rosen
    Cancer Institute Medical Group, St John s Health Center, 2001 Santa Monica Boulevard, Suite 560W, Santa Monica, CA 90404, USA
    Hematol Oncol Clin North Am 16:1173-87. 2002
    ..As we learn more about the VEGF pathways in the laboratory and the clinic, we can interpret with greater certainty what role these drugs or their successors will have in the treatment of human cancers...
  6. ncbi request reprint Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Los Angeles, California 90025, USA
    Cancer 100:2613-21. 2004
    ..In the current study, they update these results and report the long-term efficacy and safety of 21 months of treatment with zoledronic acid in a randomized, placebo-controlled trial...
  7. ncbi request reprint Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies
    Lee S Rosen
    Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA
    Clin Cancer Res 10:3689-98. 2004
    ..Patients underwent tumor assessments on day 43, and those patients receiving clinical benefit continued on treatment until disease progression or unacceptable toxicity. Safety was assessed by the WHO criteria...
  8. ncbi request reprint Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
    Lee S Rosen
    Cancer Institute Medical Group, Santa Monica, California, USA
    Cancer 100:36-43. 2004
    ..Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial...
  9. doi request reprint Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
    Roy S Herbst
    Premiere Oncology, California, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404, USA
    J Clin Oncol 27:3557-65. 2009
    ..AMG 386 also appeared to impact tumor vascularity and showed antitumor activity in this patient population...
  10. doi request reprint Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
    Jonathan W Goldman
    David Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA
    Cancer 118:5903-11. 2012
    ..This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of tivantinib combined with the EGFR inhibitor erlotinib...
  11. ncbi request reprint Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA, USA
    J Clin Oncol 25:2369-76. 2007
    ..This phase I, dose-finding study evaluated the safety, pharmacokinetics, and pharmacodynamics of AMG 706 in patients with refractory advanced solid tumors...
  12. ncbi request reprint Biologic approaches to the treatment of gastrointestinal malignancy
    Lee S Rosen
    Assistant Professor of Medicine, Division of Hematology Oncology Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California 90095, USA
    Curr Opin Oncol 14:431-8. 2002
    ..Discussed here are agents targeting the vascular endothelial growth factor as an example of an angiogenesis inhibitor, and agents targeting the epidermal growth factor receptor, the ras oncogene, and the immune system...
  13. ncbi request reprint VEGF-targeted therapy: therapeutic potential and recent advances
    Lee S Rosen
    John Wayne Cancer Institute and St John s Health Center, Santa Monica, California, USA
    Oncologist 10:382-91. 2005
    ..This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers...
  14. ncbi request reprint Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    Lee S Rosen
    Cancer Institute Medical Group, 11818 Wilshire Blvd, Suite 200, Los Angeles, CA 90025, USA
    J Clin Oncol 21:3150-7. 2003
    ..To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer...
  15. pmc A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
    Jonathan W Goldman
    UCLA Medical Center, Suite 600, 2020 Santa Monica Blvd, Santa Monica, CA 90404, USA
    BMC Cancer 13:152. 2013
    ..This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies...
  16. pmc Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review
    Lee S Rosen
    Premiere Oncology, 2020 Santa Monica Boulevard, Suite 600, Santa Monica, California 90404, USA
    Oncologist 15:216-35. 2010
    ..The aim of this review is to summarize some of the key signaling pathways involved in tumor progression and some of the novel therapies that are in development for MBC...
  17. ncbi request reprint New generation of bisphosphonates: broad clinical utility in breast and prostate cancer
    Lee S Rosen
    Cancer Institute Medical Group, Santa Monica, California, USA
    Oncology (Williston Park) 18:26-32. 2004
    ..Clinical trials addressing the treatment of bone metastases related to prostate cancer have shown zoledronic acid to be the only bisphosphonate to have a significant positive effect on skeletal-related events...
  18. ncbi request reprint Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Santa Monica, California 90095, USA
    Cancer 98:1735-44. 2003
    ..The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma...
  19. ncbi request reprint Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy
    Lee S Rosen
    Premiere Oncology, John Wayne Cancer Institute, St John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 24:5194-200. 2006
    ....
  20. doi request reprint Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
    J Clin Oncol 26:4708-13. 2008
    ..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...
  21. ncbi request reprint Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies
    Lee S Rosen
    Jonsson Comprehensive Cancer Center, University of California, Los Angeles, USA
    Clin Cancer Res 9:1628-38. 2003
    ..The purpose of this study was to determine the dose-limiting toxicities (DLTs), the maximum tolerated dose, and the pharmacokinetics of the novel glutathione analog TLK286 administered by i.v. infusion...
  22. ncbi request reprint Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma
    Maria L Delioukina
    University of California at Los Angeles Center for the Health Sciences and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
    Cancer 94:2174-9. 2002
    ....
  23. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA 90404, USA
    Clin Cancer Res 13:6853s-6s. 2007
    ....
  24. ncbi request reprint Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    Elaine Wong
    Endocrinology and Diabetes Division, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California, USA
    Thyroid 17:351-5. 2007
    ..Sunitinib is a novel tyrosine kinase inhibitor with antitumor and antiangiogenic effects. An observed higher than expected rate of hypothyroidism in sunitinib-treated patients prompted assessment of the incidence of hypothyroidism...
  25. ncbi request reprint Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors
    Lee S Rosen
    Cancer Institute Medical Group, Santa Monica, CA 90404, USA
    Semin Oncol 29:28-32. 2002
    ..This was the first demonstration of palliative efficacy for bisphosphonate therapy in patients with bone metastases from a wide variety of solid tumors...
  26. ncbi request reprint Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers
    Lee S Rosen
    UCLA Jonsson Cancer Center, Los Angeles, CA 90095 7059, USA
    Cancer Control 9:36-44. 2002
    ..Angiogenesis, the role of VEGF in angiogenesis and malignancy, and strategies for cancer treatment with VEGF inhibitors are discussed...
  27. ncbi request reprint Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note
    Anton J Bilchik
    John Wayne Cancer Institute at St John s Health Center, Santa Monica, CA, USA
    J Clin Oncol 23:9073-8. 2005
  28. doi request reprint Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
    David Hong
    Authors Affiliations Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas Biogen Idec, Cambridge, Massachusetts Genoptix Novartis, Carlsbad and UCLA Division of Hematology Oncology, Santa Monica, California
    Clin Cancer Res 19:4824-31. 2013
    ..We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of BIIB028, a prodrug designed to inhibit Hsp90 activity...